Complete response to pembrolizumab in a patient with dermatomyositis and MMR deficient ovarian cancer: A case report

• Immune checkpoint inhibitors can be safely administered to patients with dermatomyositis. • Immunosuppressants did not impact the efficacy of treatment with an immune check point inhibitor. • Patients with autoimmune disorders who require immune check point inhibitors should be monitored by a rheu...

Descripción completa

Detalles Bibliográficos
Autores principales: Valls, Maia L., Kase, Adam M., Patel, Rina, Wang, Benjamin, Aggarwal, Rohit, Colon-Otero, Gerardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9156981/
https://www.ncbi.nlm.nih.gov/pubmed/35663849
http://dx.doi.org/10.1016/j.gore.2022.101010
_version_ 1784718549786296320
author Valls, Maia L.
Kase, Adam M.
Patel, Rina
Wang, Benjamin
Aggarwal, Rohit
Colon-Otero, Gerardo
author_facet Valls, Maia L.
Kase, Adam M.
Patel, Rina
Wang, Benjamin
Aggarwal, Rohit
Colon-Otero, Gerardo
author_sort Valls, Maia L.
collection PubMed
description • Immune checkpoint inhibitors can be safely administered to patients with dermatomyositis. • Immunosuppressants did not impact the efficacy of treatment with an immune check point inhibitor. • Patients with autoimmune disorders who require immune check point inhibitors should be monitored by a rheumatologist.
format Online
Article
Text
id pubmed-9156981
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-91569812022-06-02 Complete response to pembrolizumab in a patient with dermatomyositis and MMR deficient ovarian cancer: A case report Valls, Maia L. Kase, Adam M. Patel, Rina Wang, Benjamin Aggarwal, Rohit Colon-Otero, Gerardo Gynecol Oncol Rep Case Report • Immune checkpoint inhibitors can be safely administered to patients with dermatomyositis. • Immunosuppressants did not impact the efficacy of treatment with an immune check point inhibitor. • Patients with autoimmune disorders who require immune check point inhibitors should be monitored by a rheumatologist. Elsevier 2022-05-25 /pmc/articles/PMC9156981/ /pubmed/35663849 http://dx.doi.org/10.1016/j.gore.2022.101010 Text en © 2022 The Authors. Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Valls, Maia L.
Kase, Adam M.
Patel, Rina
Wang, Benjamin
Aggarwal, Rohit
Colon-Otero, Gerardo
Complete response to pembrolizumab in a patient with dermatomyositis and MMR deficient ovarian cancer: A case report
title Complete response to pembrolizumab in a patient with dermatomyositis and MMR deficient ovarian cancer: A case report
title_full Complete response to pembrolizumab in a patient with dermatomyositis and MMR deficient ovarian cancer: A case report
title_fullStr Complete response to pembrolizumab in a patient with dermatomyositis and MMR deficient ovarian cancer: A case report
title_full_unstemmed Complete response to pembrolizumab in a patient with dermatomyositis and MMR deficient ovarian cancer: A case report
title_short Complete response to pembrolizumab in a patient with dermatomyositis and MMR deficient ovarian cancer: A case report
title_sort complete response to pembrolizumab in a patient with dermatomyositis and mmr deficient ovarian cancer: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9156981/
https://www.ncbi.nlm.nih.gov/pubmed/35663849
http://dx.doi.org/10.1016/j.gore.2022.101010
work_keys_str_mv AT vallsmaial completeresponsetopembrolizumabinapatientwithdermatomyositisandmmrdeficientovariancanceracasereport
AT kaseadamm completeresponsetopembrolizumabinapatientwithdermatomyositisandmmrdeficientovariancanceracasereport
AT patelrina completeresponsetopembrolizumabinapatientwithdermatomyositisandmmrdeficientovariancanceracasereport
AT wangbenjamin completeresponsetopembrolizumabinapatientwithdermatomyositisandmmrdeficientovariancanceracasereport
AT aggarwalrohit completeresponsetopembrolizumabinapatientwithdermatomyositisandmmrdeficientovariancanceracasereport
AT colonoterogerardo completeresponsetopembrolizumabinapatientwithdermatomyositisandmmrdeficientovariancanceracasereport

Ejemplares similares